Analysis Questions Orphan Drug Pricing Exemptions
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Orphan Cures Act expanded Medicare pricing exemptions to include drugs with multiple orphan indications, altering the original framework set by the Inflation Reduction Act
- Inflation Reduction Act originally exempted from Medicare price negotiations only those orphan drugs with a single FDA-approved rare disease indication
- Medicare may not need to delay price negotiations for orphan drugs under the new rules, according to the analysis, which questions the justification for extended protections
- One Big Beautiful Bill Act became law last year and included the Orphan Cures Act provision, broadening support for rare disease drug developers
Why it matters: Drug developers gain extended protection from Medicare price negotiations if their products qualify under multiple orphan designations, but taxpayers and the program could face higher costs if these exemptions aren't offset by increased innovation. The analysis suggests the policy change may outpace its intended purpose.
